PubRank

Nuhad Ibrahim

Author PubWeight™ 33.21‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005 9.70
2 Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006 7.24
3 A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011 4.63
4 Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004 1.70
5 Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003 1.67
6 Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 2011 1.43
7 Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005 1.40
8 Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res 2009 0.86
9 Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 2012 0.84
10 A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res 2003 0.84
11 Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist 2011 0.82
12 MUC1 glycopeptide epitopes predicted by computational glycomics. Int J Oncol 2012 0.79
13 A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs 2015 0.79
14 Therapeutic breast cancer vaccines: a new strategy for early-stage disease. BioDrugs 2009 0.78
15 Albumin-bound Paclitaxel in metastatic breast cancer: viewpoints. Drugs 2006 0.75
16 Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer. Cancer Chemother Pharmacol 2005 0.75